Alexander Sapir | executive |
Alan Musso | executive |
Corinne Jenkins | analyst |
Iain Fraser | executive |
Dae Gon Ha | analyst |
Joseph Schwartz | analyst |
Edward Tenthoff | analyst |
Matthew Biegler | analyst |
Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instruction] This call is being webcast live on the Investors section of Fulcrum's website at www.frontx.com and is being recorded. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development time lines and financial projections.
While these forward-looking statements represent Fulcrum [ rules ] as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on any obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum.
Joining Alex on the call are Alan Musso, Chief Financial Officer; and Dr.